Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains - 26/07/17
Doi : 10.1016/j.jinf.2017.03.006
Qianqian Qi
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Qian Wang
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China
Weizao Chen
Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
Fei Yu
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Dimiter S. Dimitrov
Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
Lu Lu ⁎ 
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China
∗∗Corresponding author.
Shibo Jiang ⁎
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
∗Corresponding author. Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China. Fax: +86 54237465.Key Laboratory of Medical Molecular Virology of Ministries of Education and HealthShanghai Medical CollegeFudan UniversityShanghaiChina
Highlights |
• | Combining anti-HIV antibody and drugs showed synergistic anti-HIV-1 activity. |
• | Anti-HIV antibody/drug combinations are effective against drug-resistant mutants. |
• | Combining drugs with different targets increase drug-resistance barrier. |
• | Drug combinations lead to dose-reduction, thus reducing drugs' cost and toxicity. |
Plan
© 2017
Publié par Elsevier Masson SAS.
Vol 75 - N° 1
P. 68-71 - juillet 2017 Retour au numéro
Article précédent
- ICU-acquired candidaemia in France: Epidemiology and temporal trends, 2004–2013 – A study from the REA-RAISIN network
- Olivier Baldesi, Sébastien Bailly, Stéphane Ruckly, Alain Lepape, François L'Heriteau, Martine Aupee, Sandrine Boussat, Caroline Bervas, Anais Machut, Anne Berger-Carbonne, Anne Savey, Jean François Timsit, the REA-RAISIN network l
- Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China
- Fuchun Zhang, Yuhai Bi, Jian Wang, Gary Wong, Weifeng Shi, Fengyu Hu, Yang Yang, Liuqing Yang, Xilong Deng, Songfeng Jiang, Xi He, Yingxia Liu, Chibiao Yin, Nanshan Zhong, George F. Gao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?